Immunosuppressive and Immunomodulatory Therapies for Neuromuscular Diseases Part I: Traditional Agents.

08:00 EDT 11th September 2019 | BioPortfolio

Summary of "Immunosuppressive and Immunomodulatory Therapies for Neuromuscular Diseases Part I: Traditional Agents."

Immunosuppressive and immunomodulatory therapies have had a major effect on the treatment of immune-mediated neuromuscular diseases. Following the landmark introduction of synthetic corticosteroids, other therapies have become available including plasma exchange (PLEX), immunoglobulin G (IgG), and steroid-sparing immunosuppressive drugs. More recently, novel biologically derived and antigen-specific pharmaceuticals have entered neuromuscular practice. Various levels of evidence guide the use of these medications. This article reviews current immune-based therapies in neuromuscular diseases and is divided in two parts. Part I provides an update on the evidence and use of traditional therapies, such as corticosteroids, PLEX, intravenously delivered IgG (IVIG), and steroid-sparing immunosuppressive drugs. Part II focuses on the recently FDA-approved therapies eculizumab and subcutaneous IgG (SCIG), the current indications for rituximab in neuromuscular disease, and on novel immunosuppressive therapeutic approaches underdevelopment. This article is protected by copyright. All rights reserved.


Journal Details

This article was published in the following journal.

Name: Muscle & nerve
ISSN: 1097-4598


DeepDyve research library

PubMed Articles [20965 Associated PubMed Articles listed on BioPortfolio]

Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review.

Standard treatment of cutaneous lupus erythematosus (CLE) includes preventive measures such as smoking cessation and photoprotection associated with topical therapies and antimalarial agents, which ar...

Passive immune therapy and other immunomodulatory agents for the treatment of severe influenza: Systematic review and meta-analysis.

A range of immunomodulatory therapies have been proposed as adjuncts to conventional antivirals to suppress harmful inflammation during severe influenza infection. We conducted a systematic review to ...

In vitro models of neuromuscular junctions and their potential for novel drug discovery and development.

: Neuromuscular Junctions (NMJs) are the synapses between motor neurons and skeletal muscle fibers, and they are responsible for voluntary motor function. NMJs are affected at early stages of numerous...

In vivo Immunomodulatory Activity of Faloak Bark Extract (Sterculia quadrifida R.Br).

Faloak (Sterculia quadrifida R.Br) is widely used as traditional medicine in Indonesia to improve stamina (reduce tiredness for heavy workers). However, no scientific reports so far on the immunomodul...

Presentation and management patterns of lower urinary tract symptoms in adults due to rare inherited neuromuscular diseases.

To describe the urologic sequalae of several rare congenital neuromuscular diseases.

Clinical Trials [12917 Associated Clinical Trials listed on BioPortfolio]

The Differential Effects of 3 Different Immunosuppressive

The study is a laboratory investigation comparing the regulatory effects of different immunosuppressive therapies in an in vitro human MLR assay of selecting specific immunosuppressive the...

Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal

The use of neuromuscular blocking agents during surgery is associated with postoperative respiratory complications and increased risk of readmission to the hospital following ambulatory su...

The Yi-Qi-Qing-Jie Formula Combined Immunosuppressive Agents is More Advantageous Than Only Immunosuppressive Monotherapy for the Treatment of Progressive IgA Nephropathy

This study is a prospective open-label randomized controlled clinical trial with a two-group parallel design aiming to prove the Yi-Qi-Qing-Jie formula combined immunosuppressive agents br...

Avoiding Neuromuscular Blockers to Reduce Complications

The goal of this study to evaluate whether eliminating the use of non-depolarizing neuromuscular blocking agents (NMBA) for maintenance of general anesthesia reduces postoperative pulmonar...

Effectiveness of Respiratory Physiotherapy in Children With Neuromuscular Disease

The main objective of this study is to determine whether the Respiratory Physiotherapy allows improvement or maintenance of respiratory function in children with Neuromuscular Diseases, ag...

Medical and Biotech [MESH] Definitions

Drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. They can be of two types, competitive, stabilizing blockers (NEUROMUSCULAR NONDEPOLARIZING AGENTS) or noncompetitive, depolarizing agents (NEUROMUSCULAR DEPOLARIZING AGENTS). Both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.

The use of peripheral nerve stimulation to assess transmission at the NEUROMUSCULAR JUNCTION, especially in the response to anesthetics, such as the intensity of NEUROMUSCULAR BLOCKADE by NEUROMUSCULAR BLOCKING AGENTS.

The intentional interruption of transmission at the NEUROMUSCULAR JUNCTION by external agents, usually neuromuscular blocking agents. It is distinguished from NERVE BLOCK in which nerve conduction (NEURAL CONDUCTION) is interrupted rather than neuromuscular transmission. Neuromuscular blockade is commonly used to produce MUSCLE RELAXATION as an adjunct to anesthesia during surgery and other medical procedures. It is also often used as an experimental manipulation in basic research. It is not strictly speaking anesthesia but is grouped here with anesthetic techniques. The failure of neuromuscular transmission as a result of pathological processes is not included here.

Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.

The restriction of the MOVEMENT of whole or part of the body by physical means (RESTRAINT, PHYSICAL) or chemically by ANALGESIA, or the use of TRANQUILIZING AGENTS or NEUROMUSCULAR NONDEPOLARIZING AGENTS. It includes experimental protocols used to evaluate the physiologic effects of immobility.

Quick Search

DeepDyve research library

Relevant Topics

Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Searches Linking to this Article